Draft Guidance Limits Aspirin for Heart Disease Prevention
Federal panel proposes narrowing routine aspirin use for adults without known cardiovascular disease, with public comment open until November 8, 2021.
Updated on Nov. 12, 2026 in Heart Disease

The U.S. Preventive Services Task Force released draft recommendations on October 12, 2021, on aspirin therapy for primary prevention of cardiovascular disease in adults. The draft is open for public comment until November 8, 2021, before the independent volunteer panel makes a final decision.
Why it matters
Recent large trials indicate the overall benefit of aspirin is small, and for most adults that benefit is offset by potential bleeding risk. Because more than 80% of cardiovascular events may be prevented through lifestyle changes, the draft points readers toward prevention habits alongside medication decisions.
The draft guidance cites a public comment deadline of November 8, 2021, and states that more than 80% of cardiovascular events may be prevented by lifestyle changes. The extraction does not specify the final decision or how many comments were received.
The players
U.S. Preventive Services Task Force
An independent, volunteer panel of medical experts that issues evidence-based recommendations on preventive care services for the U.S. public.
American Heart Association
A leading nonprofit organization focused on heart disease and stroke research, prevention and advocacy in the United States.
The details
The Task Force posted the draft for public comment rather than issuing final guidance, and the recommendations do not apply to people who have already had a heart attack or stroke or who have an artery stent. The American Heart Association separately issued a statement supporting selective aspirin use in adults without known cardiovascular disease.
Timeline
October 12, 2021: The U.S. Preventive Services Task Force released its draft aspirin recommendations.
November 8, 2021: The public comment period on the draft recommendations closes.
Health Landscape
The draft follows the 2019 American College of Cardiology and American Heart Association primary prevention guidance on aspirin, reflecting a narrowing view of aspirin's benefit as newer trial evidence accumulates. It places greater emphasis on lifestyle measures as the primary route to reducing cardiovascular risk.
Adults without known heart disease may want to discuss with their clinicians whether daily aspirin is appropriate, since the draft suggests it should rarely be used for those ages 40-70 given bleeding risk. Lifestyle changes remain a key focus for lowering cardiovascular risk.
The takeaway
Talk with your clinician before starting or continuing daily aspirin for heart protection, since bleeding risk can outweigh the modest benefit for many adults. Lifestyle habits such as diet, exercise and not smoking remain central to preventing cardiovascular disease.
What happens next
The U.S. Preventive Services Task Force will review public comments received through November 8, 2021 before issuing a final recommendation.
Further reading
For more on prevention strategies, see our Heart Disease coverage.
Source note: This article includes information reported by American Heart Association.






